Psychosocial controversies in breast cancer by Fallowfield, Lesley
Available online http://breast-cancer-research.com/content/9/S2/S2
Page 1 of 3
(page number not for citation purposes)
The many exciting advances in breast cancer treatment made
over the past decade mean that more women are now cured
of their disease or are living longer with a better quality of life
(QoL). These research-driven improvements in care have
taken place against a backdrop of many other societal and
cultural changes, which in themselves are now influencing the
content and conduct of both research and clinical practice.
For some time now medical care has had a more patient-
centred focus, with patients expecting to be given more
autonomy as a partner in determining their own treatment
rather than merely a passive recipient of paternalistic care.
Patients expect to be treated with dignity and respect, to be
given clear information about their disease and invited to
choose between the possible therapeutic options. To be able
to deliver on these expectations, many health care profes-
sionals need better communication skills training. Attitudinal
shifts are also required, which can be difficult for some who
are educated within different cultures and more hierarchically
based systems.
Breast cancer advocacy groups worldwide have put breast
cancer very firmly on the political agenda. Their lobbying has
undoubtedly led to better quality breast cancer care, which is
a model envied by those working in other tumour sites. Some
providers of cancer services feel that breast cancer patients,
because of their high profile, relentless activity and celebrity
supporters, may be getting more of the health care budget
than is fair.
Patient representatives now play a formal role on most clinical
trial steering committees. In the past their role was often
tolerated rather than welcomed, but some have earned their
place at the table by making valuable contributions to
discussions not only about patient information sheets but also
about the likely feasibility that a trial and its subprotocols will
be acceptable to other patients. As these individuals and the
groups supporting them have become more powerful, they
have also demanded a greater say in the type of research that
is conducted. Because it is often charitable groups that raise
much of the money to pay for research, it seems only
reasonable that they should have a say in what research is
done; this is leading to tensions, particularly among basic,
blue skies researchers who feel that the complexity and
potential utility of their type of work is unfathomable and
unattractive to laypeople compared with, say, supportive care
research looking at pain relief or massage therapy.
Although new systemic treatments for breast cancer have
improved the outlook for patients in terms of disease-free and
overall survival, many women will experience side effects that
are often underestimated and consequently under-treated. In
adjuvant treatment for early breast cancer, many women who
have already successfully been treated with surgery and
radiotherapy have chemotherapy or hormone therapy, from
which they will derive no further benefit and merely iatrogenic
harms. This can affect adherence and, if side effects are not
dealt with adequately, push patients into the arms of
alternative and complementary therapists. Although there is a
literature accumulating showing measurable benefits in terms
of reduction in stress, pain and vasomotor complaints from
such things as aromatherapy, therapeutic massage and
acupuncture, other areas such as homeopathy have no
evidence base and arouse polarized and passionate debate.
There are major concerns about the volume of non-
prescription drugs that patients are taking, which at the very
least damage their bank balances but at worst seriously
interfere with their anticancer treatments. Unless side effects
are measured and monitored adequately within clinics, it will
not be possible to collect data demonstrating the non-life-
threatening but QoL-threatening side effects that
compromise adherence or that send women running to
complementary therapists. This is bad enough in an adjuvant
setting, but it is not acceptable in advanced metastatic
disease, where preserving QoL may be the only criterion of
benefit. We have excellent psychometric tools with which to
measure QoL, and evidence is accumulating that they have
predictive value that could help to guide management. It is
rare outside a clinical trial to see formal assessment of QoL.
In contrast, despite their dubious utility, much energy is
invested in measuring tumour markers.
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The following eight papers establish the case for and against
some of the issues raised, including patient representation,
patient advocacy, QoL, and decision making about surgical
therapy and complementary therapy. The invited audience
were asked to vote on the questions or statements shown
below before the talks and then after a discussion period. The
results are summarized in Table 1.
Regarding patient representation, after the talks it was
agreed that it was really impossible to find a ‘generic’ patient
to represent all. There was a shift toward the view that
patients’ presence was not necessarily always helpful but
recognition of political correctness would make change
impossible, especially in the USA. With respect to whether
patients should be involved in clinical trial design, it was clear
that patient priorities would be very different and likely that
much basic science would never be supported. Regarding
advocacy groups, the audience were all working in breast
cancer and recognized that patient advocacy groups were
undoubtedly very powerful in getting access to new drugs. It
was also recognized that it would always be impossible to
find activists as powerful for other tumours, such as lung or
colorectal, and so breast is unlikely to be a ‘model’ for these
sites.
Sufficient evidence was provided demonstrating that patient
self-reports are more accurate than data from physician
completed case report forms (CRFs). QoL questionnaires are
Table 1
Audience responses to questions before the talks and after the discussion period
Before/after discussion Yes No Unsure
Is patient representation on trial steering committees helpful?
Before 53 16 32
After 44 38 18
Should patients be involved in clinical trial design?
Before 38 39 23
After 32 56 11
Do patient advocacy groups help speed up introduction of new drugs in the clinic?
Before 63 24 13
After 90 8 2
Are patient advocacy groups responsible for distorting cancer budget in favour of breast over other tumours?
Before 79 11 10
After 66 30 5
Should formal QoL play a major role in the management of MBC patients?
Before 73 14 14
After 90 8 2
Are patient self-reports in QoL questionnaires more accurate than clinicians’ records of side effects?
Before 50 25 25
After 80 8 13
When making decisions about local surgical therapy women prefer …a
Before 10 (Dr to choose) 83 (joint decision) 7 (patient choice)
After 5 (Dr to choose) 81 (joint decision) 14 (patient choice)
Should breast cancer patients be encouraged to try complementary therapy?
Before 23 48 29
After 31 38 31
Do nonprescription drugs help the symptoms and side effects?
Before 39 20 41
After 38 23 39
aFor this question, the options were ‘Dr to choose’, ‘joint decision’ and ‘patient choice’. MBC, metastatic breast cancer; QoL, quality of life.Available online http://breast-cancer-research.com/content/9/S2/S2
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used routinely in clinical trials. It is therefore unclear why they
are not used to guide management of metastatic breast
cancer because tumour markers are not always feasible,
available, or helpful. Technology (touch screens) exist to help
administration of questionnaires.
Data were presented showing that there were discrepancies
between patient’s and doctors’ views as to how decisions are
made. Some of the audience were persuaded that patient
choice was something many but not all women wanted.
The session on complementary therapy produced the liveliest
debate. Semantics proved important because many things
are included under the umbrella of complementary and
alternative medicine (CAM). There were many assertions
made for CAM benefits but no really hard data were offered
in support during the session. Concerns were raised about
endorsement by celebrities and sportsmen. Finally, there are
differences in criteria for acceptance of treatments:
conventional drugs go through rigorous testing and their
labelling is regulated, but this is not the case for CAM.
On the issue of symptoms and side effects, despite few data
demonstrating efficacy beyond a placebo effect, many
patients take nonprescription drugs that could seriously inter-
fere with breast cancer treatments. Better communication is
needed about side effects, as is more research to ameliorate
unpleasant symptoms associated with breast cancer treatment.
There are many psychosocial and ethical controversies in the
field of breast cancer. These are rarely discussed thoroughly
by multidisciplinary groups of clinicians and scientists
together. Such important topics are usually relegated to small
parallel symposia attended by social scientists. The issues
debated affect all - patients, clinicians and scientists - and
they are worthy of more discussion.
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